Last week, Jeremy Hunt, Chancellor of the Exchequer, published his Spring Budget for the UK. It identified life sciences and digital technologies as “high growth sectors,” which the UK Government wishes to prioritize. Among other things, the Budget outlined the Government’s plans to simplify medicines and technology approvals
Continue Reading UK MHRA to recognize foreign regulatory approvals for medicines and medical technologies and promote digital innovation
Roderick Dirkzwager
Roderick Dirkzwager advises clients in the life sciences sector on a broad range of regulatory, transactional and intellectual property matters relating to the discovery, development and commercialization of their products.
Roderick is a member of Covington’s Diversity and Inclusion Committee and is a co-lead of the LGBT+ Affinity Group in London.
With a broad life sciences practice, Roderick regularly advises on:
- EU, Irish, and UK regulatory issues relating to pharmaceutical products and medical devices;
- commercial agreements that span the product life-cycle in the life sciences sector, including collaborations and other strategic agreements, clinical trial agreements, distribution arrangements and manufacturing and supply contracts;
- regulatory and commercial due diligence for life sciences transactions; and
- intellectual property issues arising in corporate transactions and IP-related contracts.
Roderick is also a member of Covington's Life Sciences in Africa team and advises clients on regulatory and commercial strategies for the supply of medical products across Africa, including through international recognition procedures such as WHO pre-qualification. Prior to joining the firm, Roderick completed his Ph.D. in Biochemistry, focusing on the development of novel, low-cost malaria diagnostic technologies using DNA aptamers.